Stem Cell Therapy Hair Treatment: What to Expect, Step by Step
Introduction: Inside the Stem Cell Hair Clinic
People researching stem cell therapy for hair loss tend to find two kinds of information. Clinic marketing pages describe the procedure in detail: the consultation, the harvesting, the injections, the quick recovery. They usually say little about the evidence behind it. Skeptical “reality check” articles take the opposite approach. They cite regulatory status and clinical data, but they rarely explain what a patient actually goes through in the treatment chair.
This article combines both views. It follows a typical patient from the first consultation to the final results check, and it places the regulatory status and clinical evidence at the points where they affect each decision.
One fact applies to every step: as of 2026, no stem cell hair treatment has FDA approval in the United States. That is not a minor caveat. It shapes how candidates are screened, how consent should be handled, and how results should be judged.
The walkthrough covers the two procedures patients most often encounter:
- Autologous adipose-derived stem cell (ADSC) therapy, which uses cells taken from the patient’s own fat
- Stem cell-PRP combination treatments, a non-surgical blended approach
What “Stem Cell Therapy” Actually Means (and What It Doesn’t)
Clinic marketing often uses “stem cell therapy” to describe several different treatments, so it helps to define the terms first.
True stem cell therapy introduces regenerative cells into the scalp. These are often derived from adipose (fat) tissue, and the goal is to reactivate dormant or damaged hair follicles.
Platelet-rich plasma (PRP) works differently. It concentrates the patient’s own platelets and growth factors to stimulate follicles that are still active. PRP does not introduce new regenerative cells, though clinics frequently and inaccurately treat the two as interchangeable.
Exosome therapy is a third category that is often confused with the other two. Exosome products usually contain no live cells at all. According to the Journal of the American Academy of Dermatology, human research on exosomes for hair growth is extremely limited.
The labeling problems extend further: regulatory and industry analyses have found that many “umbilical cord” or “amniotic” stem cell products sold by clinics contain no live stem cells, only cellular debris or growth factors.
Outside the United States, one regulated treatment does exist. Shiseido’s S-DSC therapy, launched in Japan in July 2024, is considered the first commercial stem cell hair treatment in the world. It harvests the patient’s own dermal sheath cup cells, expands them in a laboratory, and reinjects them, producing modest hair thickening. The therapy is not available outside Japan and is not approved anywhere else.
The U.S. regulatory baseline: Only two medications are FDA-approved for androgenetic alopecia (pattern hair loss): minoxidil and finasteride. No new drug for pattern hair loss has been approved in nearly three decades. Every stem cell hair therapy sold commercially in the U.S. is investigational.
Step 1: Consultation and Candidacy Screening
The first visit should look like a standard dermatology evaluation for hair loss. It typically includes:
- A detailed scalp and hair examination
- A review of medical history, including medications and family history of hair loss
- A discussion of the pattern of hair loss, when it started, and how quickly it is progressing
These steps matter because candidacy depends on what kind of hair loss a patient has, not just the fact that hair is thinning. Different types of alopecia respond very differently to regenerative treatment.
Who Responds Best and Who Doesn’t
Strongest candidates: Stem cell therapy performs best in people with early-to-moderate androgenetic alopecia. In these patients, follicles are miniaturized or only partly active but have not been destroyed, giving the therapy something to work with.
Poor candidates: In scarring (cicatricial) alopecia, the follicles themselves are destroyed, and response to stem cell therapy is minimal or absent. There is one notable exception. A study published through the National Institutes of Health found that treating scarred tissue with stem cells before follicular unit extraction (FUE) transplantation improved hair density by 45% and achieved 87% graft survival. Patients with scarring should ask whether stem cells might play a supporting role alongside a transplant, rather than serving as a standalone treatment.
Uncertain candidates: Evidence for alopecia areata, an autoimmune form of hair loss, is still limited. Patients with this condition should keep their expectations modest.
A reputable clinic will turn away poor candidates rather than treat everyone who walks in. If a provider says a patient is a good fit without first identifying the type of hair loss, that is a warning sign.
Verifying Legitimacy Before Booking
Before committing, patients can run one practical check: ask the clinic for its Investigational New Drug (IND) application number. If the clinic does not have one, the treatment has no formal regulatory standing in the U.S.
This check carries more weight now than it once did. The FDA’s 2017 public warning about unproven stem cell therapies is still fully in effect in 2026, and enforcement has increased. In 2025 and 2026, the agency sent warning letters to clinics including Chara Biologics, New Life Medical Services, R3 Medical Companies, and Dynamic Stem Cell Therapy. It also sent letters to additional clinics in Florida, California, and Texas for marketing unapproved biologics.
Patients should also ask directly whether the product is:
- Autologous: made from the patient’s own cells, such as fat harvested during the procedure
- Allogeneic: derived from donor material, such as umbilical cord or amniotic tissue
The answer affects both the product’s legal status and its risk profile. Donor-derived products have been a frequent target of FDA enforcement.
Step 2: Day-of Preparation
Clinics typically give instructions in the days before treatment, especially when sedation will be used. Common guidance includes:
- Fasting or dietary instructions if an oral sedative is planned
- Arranging a ride home, since driving after sedation is unsafe
- Avoiding blood thinners and certain supplements, as directed by the provider, to reduce bruising and bleeding
On the day of treatment, the clinic should confirm which procedure the patient is receiving and explain why it was chosen during the consultation. The two options are surgical ADSC extraction and a non-surgical stem cell-PRP combination.
Informed consent is an important part of this step. Patients should be told clearly that:
- The treatment is investigational and not FDA-approved
- Results vary between individuals
- Insurance does not cover the procedure
Visit length should also be discussed. The ADSC procedure usually takes about three hours in total. The non-surgical PRP-combination version takes about an hour.
Step 3: Inside the Procedure Room: Extraction, Processing, and Injection
This is the main part of the clinic visit. What happens depends on which of the two procedures the patient is receiving.
The ADSC (Adipose-Derived Stem Cell) Pathway
Extraction. The procedure starts with a mini-liposuction, usually from the abdomen or flanks. It is performed under local anesthesia, often with a mild oral sedative, and takes about 20 minutes.
Processing. The fat is processed in the office, either mechanically or enzymatically, to isolate and concentrate the stem cells. These cells are often part of what is called the stromal vascular fraction (SVF), a mix of regenerative cells found in fat tissue. Registered trials such as one listed on ClinicalTrials.gov have studied SVF-based approaches for androgenetic alopecia.
Injection. The concentrated cells are injected into thinning areas of the scalp with fine needles. This completes the outpatient visit, which lasts about three hours in total.
What the evidence shows. A frequently cited 2017 Italian pilot study by Gentile and colleagues, published in Stem Cell Investigation, reported about a 29% increase in hair density in under two months using stem cell therapy alone. However, the study included fewer than a dozen participants, which limits how far the results can be applied to other patients.
The Stem Cell-PRP Combination Pathway
The non-surgical option follows a different sequence:
- Blood draw: A standard blood sample is taken and spun in a centrifuge to isolate platelets and growth factors (PRP).
- Scalp preparation: The scalp is numbed and then microneedled, which may help the treatment reach the follicles.
- Injection: The combined stem cell-PRP mixture is injected into thinning areas.
The whole process takes about an hour, making it much shorter and less invasive than the liposuction-based procedure.
Clinics promote this combination because it pairs PRP’s stimulating effect on existing follicles with the regenerative potential of stem cells. Patients should know, though, that the combination has less independent trial data than either treatment on its own.
Step 4: Immediate Aftercare and the First 72 Hours
Getting home. Patients who have the ADSC procedure need a ride home arranged in advance because of the sedation used during extraction.
What patients typically feel. Common short-term effects include:
- Mild soreness at the scalp injection sites
- Soreness at the liposuction donor site (ADSC procedure only)
- Temporary swelling, redness, or bruising
- Occasionally, minor scarring at the donor site
Return to routine. Most patients return to normal activities within 2 to 3 days. By comparison, recovery after a traditional FUE hair transplant usually takes one to two weeks.
An honest safety summary. Serious adverse events are rare in published trials. Minor injection-site reactions, however, are common. Patients should expect some temporary discomfort while also understanding that serious complications have seldom been reported in controlled studies.
Step 5: The Results Timeline: What to Realistically Expect
Stem cell therapy works slowly. Patients who expect visible changes within weeks are likely to be disappointed.
Months 1 to 6: Early Signals
Early improvements usually become visible 4 to 6 months after treatment. This is somewhat slower than PRP alone, which tends to show changes within 3 to 6 months.
The strongest controlled evidence for this period comes from a randomized, double-blind trial published in Stem Cells Translational Medicine. It reported a 28.1% increase in hair count compared with 7.1% for the control group over 16 weeks.
More broadly, small ADSC trials show density increases of 20% to 30% over six months. That range is a more useful benchmark than marketing claims such as “dramatic regrowth.”
Months 6 to 18: Full Effect and Long-Term Variability
The full effects of investigational stem cell therapies usually appear at 12 to 18 months.
The broadest view of the evidence comes from a 2024 systematic review in Plastic & Reconstructive Surgery – Global Open. It analyzed 12 randomized controlled trials involving 514 patients who received cellular and acellular stem cell-derived therapies. The review found consistent improvements in hair density and a favorable safety profile. It also cautioned that outcomes may be temporary and vary between patients.
That caution addresses the question many patients ask: does it last? At present, no one knows for certain. How much patients respond, and how long the results hold, are among the main unanswered questions in current research.
Research is active. More than 4,900 clinical trials exploring stem cell therapy for hair loss are underway worldwide. Long-term durability data, however, is still limited.
Step 6: Follow-Up and Maintenance
A typical follow-up schedule includes:
- A check-in at 4 to 6 months to photograph the scalp and assess early density changes
- A check-in at 12 months to evaluate the fuller effect
Many clinics recommend combining stem cell treatment with FDA-approved maintenance therapies such as minoxidil or finasteride. The reason is important: stem cell therapy does not stop the hormonal process that drives androgenetic alopecia. Without ongoing management, hair loss may continue even after a good initial response.
Some patients choose repeat sessions depending on how they respond. The evidence for repeat sessions is even more limited than the data for single sessions.
Demand for these treatments is high. The U.S. market for PRP and stem cell alopecia treatments reached about $279.88 million in 2025, even though there are no FDA-approved stem cell products. That figure reflects patient interest, not proof that the treatments work.
Weighing Stem Cell Therapy Against Other Options
| Option | Mechanism | Invasiveness | Evidence Strength |
|---|---|---|---|
| Stem cell therapy (ADSC) | Introduces regenerative cells to reactivate follicles | Moderate (mini-liposuction plus injections) | Promising but based on small trials; investigational |
| Stem cell-PRP combination | Combines growth factors with regenerative cells | Low to moderate (blood draw, microneedling, injections) | Less independent data than either treatment alone |
| PRP alone | Concentrated growth factors stimulate existing follicles | Low (blood draw and injections) | Moderate; more widely studied |
| FUE/FUT transplantation | Moves existing follicles to thinning areas | High (surgical) | Well established |
| Minoxidil / finasteride | Topical stimulation / hormonal blocking | Non-invasive | FDA-approved; strongest evidence |
Cost. Stem cell therapy costs significantly more out of pocket than PRP. Insurance does not cover any treatment in this category.
Why patients consider it. No new drug for pattern hair loss has been approved in nearly three decades. That long gap helps explain why patients and clinics turn to investigational options despite the uncertainty.
Who might reasonably consider it now: Adults with early-to-moderate androgenetic alopecia who want a non-surgical option, ideally alongside established treatments, and who understand that the treatment is investigational.
Who should likely wait or try proven options first: People with scarring alopecia (unless stem cells are used to support a transplant), people with alopecia areata, people who have not yet tried minoxidil or finasteride, and anyone who expects a guaranteed result.
What’s on the Horizon: Pipeline Treatments to Watch
The most advanced candidate in development is Pelage Pharmaceuticals’ PP405. It is a topical small-molecule drug that targets dormant hair follicle stem cells through a lactate/LDH metabolic pathway. In Phase 2a trials, 31% of male participants achieved a hair density increase of 20% or more. Dermatology trade press reported that the drug was well tolerated and showed no systemic absorption. PP405 entered Phase 3 trials in 2026 after the company completed a $120 million Series B funding round.
Other candidates in development include RepliCel’s RCH-01 and Eirion’s ET-02. Neither is currently available to patients.
These developments matter for anyone deciding whether to proceed now. Today’s investigational clinic treatments may eventually be replaced by regulated drugs with stronger evidence. Some patients may reasonably decide that waiting is the better choice.
Conclusion: Making an Informed Decision
The typical stem cell hair treatment follows a clear sequence:
- Consultation and candidacy screening
- Day-of preparation
- Extraction, processing, and injection
- A short recovery of 2 to 3 days
- A results timeline of 4 to 18 months
The evidence is mixed. Small trials are encouraging, including the Gentile 2017 pilot study, the Stem Cells Translational Medicine randomized trial, and the 2024 PRS-Global Open systematic review. At the same time, no stem cell hair treatment is FDA-approved in 2026.
The procedure is best viewed as a carefully considered investigational choice, not a guaranteed cure. The IND-number check, the autologous-versus-allogeneic question, and the candidacy criteria described above are practical tools for making that choice. A patient who understands both the procedure and the evidence is better able to evaluate any clinic’s claims.
Next Steps: Talk to a Qualified Provider
Patients considering this treatment should look for a provider who performs a genuine candidacy screening rather than a sales pitch. It helps to bring these questions to the consultation:
- What type of hair loss do I have, and am I a good candidate?
- Does this treatment have an IND application number?
- Is the product autologous or allogeneic?
- What results are realistic at 6, 12, and 18 months?
- Should I combine this with minoxidil or finasteride?
This walkthrough can serve as a checklist during the consultation, so patients can compare what they are told with what the evidence supports. Readers who want to continue their research can explore further resources from Adiamed, or contact a qualified provider to discuss their individual candidacy.
